LT3659B - Orally adminsterable drugs for the treatmentof central dopamine deficiency conditions - Google Patents
Orally adminsterable drugs for the treatmentof central dopamine deficiency conditions Download PDFInfo
- Publication number
- LT3659B LT3659B LTIP555A LTIP555A LT3659B LT 3659 B LT3659 B LT 3659B LT IP555 A LTIP555 A LT IP555A LT IP555 A LTIP555 A LT IP555A LT 3659 B LT3659 B LT 3659B
- Authority
- LT
- Lithuania
- Prior art keywords
- weight
- parts
- polyvinyl alcohol
- pva
- surface area
- Prior art date
Links
- 239000003814 drug Substances 0.000 title claims abstract description 37
- 229940079593 drug Drugs 0.000 title claims abstract description 24
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 title claims abstract description 12
- 229960003638 dopamine Drugs 0.000 title claims abstract description 6
- 230000007812 deficiency Effects 0.000 title claims abstract description 4
- 229920002451 polyvinyl alcohol Polymers 0.000 claims abstract description 39
- 239000004372 Polyvinyl alcohol Substances 0.000 claims abstract description 31
- 239000000203 mixture Substances 0.000 claims abstract description 17
- 229960004205 carbidopa Drugs 0.000 claims abstract description 15
- TZFNLOMSOLWIDK-JTQLQIEISA-N carbidopa (anhydrous) Chemical compound NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 TZFNLOMSOLWIDK-JTQLQIEISA-N 0.000 claims abstract description 15
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims abstract description 6
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims abstract description 6
- 229960004502 levodopa Drugs 0.000 claims abstract description 6
- 239000011148 porous material Substances 0.000 claims abstract description 5
- 229920002959 polymer blend Polymers 0.000 claims abstract description 4
- 238000011282 treatment Methods 0.000 claims abstract description 3
- 235000019422 polyvinyl alcohol Nutrition 0.000 claims description 37
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 7
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 7
- 230000008569 process Effects 0.000 claims description 4
- 239000008186 active pharmaceutical agent Substances 0.000 claims description 3
- 229940088679 drug related substance Drugs 0.000 claims description 3
- 229920000642 polymer Polymers 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 238000009472 formulation Methods 0.000 abstract description 3
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 abstract 2
- 239000002671 adjuvant Substances 0.000 abstract 1
- 239000013583 drug formulation Substances 0.000 abstract 1
- 239000003826 tablet Substances 0.000 description 9
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 7
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- IVTMXOXVAHXCHI-YXLMWLKOSA-N (2s)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid;(2s)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1.NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 IVTMXOXVAHXCHI-YXLMWLKOSA-N 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 238000007906 compression Methods 0.000 description 3
- 230000006835 compression Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 208000018737 Parkinson disease Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 102100038238 Aromatic-L-amino-acid decarboxylase Human genes 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 208000019430 Motor disease Diseases 0.000 description 1
- 206010034010 Parkinsonism Diseases 0.000 description 1
- 108010035075 Tyrosine decarboxylase Proteins 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 210000004227 basal ganglia Anatomy 0.000 description 1
- BNQDCRGUHNALGH-UHFFFAOYSA-N benserazide Chemical compound OCC(N)C(=O)NNCC1=CC=C(O)C(O)=C1O BNQDCRGUHNALGH-UHFFFAOYSA-N 0.000 description 1
- 229960000911 benserazide Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000035 biogenic effect Effects 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 210000001653 corpus striatum Anatomy 0.000 description 1
- 238000006114 decarboxylation reaction Methods 0.000 description 1
- 210000005064 dopaminergic neuron Anatomy 0.000 description 1
- 230000003291 dopaminomimetic effect Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000007659 motor function Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000012958 reprocessing Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229910052814 silicon oxide Inorganic materials 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE4101873A DE4101873C2 (de) | 1991-01-23 | 1991-01-23 | Peroral applizierbare Arzneiform zur Behandlung zentraler Dopaminmangelzustände |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| LTIP555A LTIP555A (en) | 1994-11-25 |
| LT3659B true LT3659B (en) | 1996-01-25 |
Family
ID=6423528
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LTIP555A LT3659B (en) | 1991-01-23 | 1993-05-14 | Orally adminsterable drugs for the treatmentof central dopamine deficiency conditions |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US5532274A (fi) |
| EP (1) | EP0568577B1 (fi) |
| JP (1) | JP3382940B2 (fi) |
| AT (1) | ATE147264T1 (fi) |
| AU (1) | AU658171B2 (fi) |
| BG (1) | BG61677B1 (fi) |
| CA (1) | CA2101164C (fi) |
| CZ (1) | CZ280847B6 (fi) |
| DE (2) | DE4101873C2 (fi) |
| DK (1) | DK0568577T3 (fi) |
| EE (1) | EE03016B1 (fi) |
| ES (1) | ES2098496T3 (fi) |
| FI (1) | FI101040B (fi) |
| GR (1) | GR3022993T3 (fi) |
| LT (1) | LT3659B (fi) |
| LV (1) | LV11103B (fi) |
| NO (1) | NO304638B1 (fi) |
| RO (1) | RO114737B1 (fi) |
| RU (1) | RU2114619C1 (fi) |
| SK (1) | SK278736B6 (fi) |
| UA (1) | UA27848C2 (fi) |
| WO (1) | WO1992012710A1 (fi) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6756056B2 (en) * | 1997-04-08 | 2004-06-29 | Alan A. Rubin | Treatment of Parkinson's disease and related disorders by novel formulations of the combination carbidopa-levodopa |
| FI109453B (fi) * | 1999-06-30 | 2002-08-15 | Orion Yhtymae Oyj | Farmaseuttinen koostumus |
| RU2173150C1 (ru) * | 2000-06-27 | 2001-09-10 | Васильев Виталий Николаевич | Фармацевтическая композиция для биокоррекции симпатико-адреналовой системы |
| US6531153B2 (en) | 2001-05-29 | 2003-03-11 | Drugtech Corporation | Composition with sustained release of levodopa and carbidopa |
| HUP0401686A3 (en) * | 2001-09-28 | 2008-04-28 | Mcneil Ppc Inc | Dosage forms having an inner core and outer shell with different shapes |
| US20040180086A1 (en) * | 2002-10-11 | 2004-09-16 | Zebunnissa Ramtoola | Gastro-retentive levodopa delivery form |
| US8815950B2 (en) * | 2003-08-29 | 2014-08-26 | Janssen Biotech, Inc. | Pharmaceutical compositions and method of using levodopa and carbidopa |
| CA2536175C (en) * | 2003-08-29 | 2013-05-28 | Transform Pharmaceuticals, Inc. | Pharmaceutical compositions and method of using levodopa and carbidopa |
| CN1845728B (zh) * | 2003-08-29 | 2013-06-19 | 转化医药公司 | 包含左旋多巴和卡比多巴的药物组合物 |
| JP4781352B2 (ja) * | 2004-06-04 | 2011-09-28 | ゼノポート，インコーポレーテッド | レボドパプロドラッグおよびその組成物ならびにその使用 |
| MX2007011976A (es) * | 2005-03-28 | 2007-12-07 | Orexo Ab | Composiciones farmaceuticas novedosas utiles en el tratamiento de la enfermedad de parkinson. |
| US20070003621A1 (en) * | 2005-06-23 | 2007-01-04 | Spherics, Inc. | Dosage forms for movement disorder treatment |
| AR055106A1 (es) * | 2005-08-05 | 2007-08-08 | Osmotica Pharmaceutical Argent | Composicion farmaceutica solida de liberacion extendida que contiene carbidopa y levodopa |
| US20080131492A1 (en) * | 2006-06-23 | 2008-06-05 | Spherics, Inc. | Dosage forms for movement disorder treatment |
| US20100316712A1 (en) * | 2006-12-22 | 2010-12-16 | Combinatorx, Incorporated | Pharmaceutical compositions for treatment of parkinson's disease and related disorders |
| KR101752080B1 (ko) | 2007-12-28 | 2017-06-28 | 임팩스 라보라토리즈, 인코포레이티드 | 레보도파 방출 제어형 제제 및 이의 용도 |
| EP2233131A1 (en) * | 2009-03-23 | 2010-09-29 | Laboratorios Lesvi, S.L. | Pharmaceutical composition containing levodopa, entacapone and carbidopa |
| KR20130009553A (ko) * | 2011-07-15 | 2013-01-23 | 한미약품 주식회사 | 몬테루카스트 또는 이의 약학적으로 허용가능한 염 및 레보세티리진 또는 이의 약학적으로 허용가능한 염을 함유하는 캡슐 제제 |
| ES2823000T3 (es) | 2013-10-07 | 2021-05-05 | Impax Laboratories Llc | Formulaciones muco-adhesivas de liberación controlada de levodopa y/o ésteres de levodopa y usos de las mismas |
| US10987313B2 (en) | 2013-10-07 | 2021-04-27 | Impax Laboratories, Llc | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof |
| JP7066351B2 (ja) * | 2017-08-18 | 2022-05-13 | 大原薬品工業株式会社 | 良好な徐放性を有する、レボドパ含有小型化錠剤 |
| CN112955136A (zh) * | 2018-11-13 | 2021-06-11 | 日本瓦姆&珀巴尔株式会社 | 粘结剂 |
| JP6694564B1 (ja) * | 2018-11-13 | 2020-05-13 | 日本酢ビ・ポバール株式会社 | 結合剤 |
| JP6695013B1 (ja) * | 2018-11-13 | 2020-05-20 | 日本酢ビ・ポバール株式会社 | 結合剤 |
| CN112969455A (zh) * | 2018-11-13 | 2021-06-15 | 日本瓦姆&珀巴尔株式会社 | 粘结剂 |
| CN115397469A (zh) * | 2020-04-10 | 2022-11-25 | 日本瓦姆&珀巴尔株式会社 | 粘合剂 |
| EP4249108A4 (en) * | 2020-11-19 | 2024-04-17 | Asahi Kasei Kabushiki Kaisha | POROUS MEMBRANE |
| US11986449B2 (en) | 2020-12-22 | 2024-05-21 | Amneal Pharmaceuticals Llc | Levodopa dosing regimen |
| JP2024501235A (ja) | 2020-12-22 | 2024-01-11 | アムニール ファーマスーティカルズ エルエルシー | レボドパ投薬レジメン |
Citations (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1243474A (en) | 1968-10-01 | 1971-08-18 | Merck & Co Inc | Compositions comprising l-dopa |
| US3769424A (en) | 1970-10-01 | 1973-10-30 | Merck & Co Inc | Composition and method of treating dopamine deficiency in brain tissue |
| DE3012602A1 (de) | 1979-04-26 | 1980-11-06 | Merrell Toraude & Co | 1-fluor-3-phenyl-2-propanon-derivate und verfahren zu ihrer herstellung |
| BE894376A (fr) | 1981-09-14 | 1983-03-14 | Hoffmann La Roche | Preparation pharmaceutique |
| DE3235093A1 (de) | 1981-09-22 | 1983-04-07 | Akira Suita Osaka Hayashi | Antiparkinsonmittel |
| US4424235A (en) | 1981-09-14 | 1984-01-03 | Hoffmann-La Roche Inc. | Hydrodynamically balanced controlled release compositions containing L-dopa and a decarboxylase inhibitor |
| EP0253490A1 (en) | 1986-06-16 | 1988-01-20 | Merck & Co. Inc. | Controlled release combination of carbidopa/levodopa |
| EP0260236A1 (en) | 1986-08-26 | 1988-03-16 | ASTA Pharma Aktiengesellschaft | Composition comprising L-dopa |
| EP0302693A2 (en) | 1987-08-03 | 1989-02-08 | Merck & Co. Inc. | Device for the controlled release of drugs with donnanlike modulation by charged insoluble resins |
| EP0314206A1 (en) | 1987-09-24 | 1989-05-03 | Merck & Co. Inc. | Solubility modulated drug delivery device |
| EP0320051A1 (en) | 1987-12-11 | 1989-06-14 | Merck & Co. Inc. | Controlled release combination of carbidopa/levodopa |
| DE3841955A1 (de) | 1987-12-31 | 1989-07-13 | Asta Pharma Ag | Synergistische kombination von decarboxylasehemmern und l-dopa-pellets |
| EP0324947A1 (de) | 1987-12-31 | 1989-07-26 | ASTA Medica Aktiengesellschaft | Synergistische Kombination von Decarboxylasehemmern und L-Dopa-Pellets |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE631201C (de) * | 1932-08-07 | 1936-06-16 | Chemische Forschungs Gmbh | Traegerstoff fuer Arzneimittel |
| DE748317C (de) * | 1941-08-17 | 1944-12-19 | Wacker Chemie Gmbh | Verfahren zur Herstellung in Wasser zerfallender Faeden, Filme, Baender, Schlaeuche u. dgl. aus unvollstaendig verseiften Polyvinylalkoholen |
| US3584113A (en) * | 1967-08-31 | 1971-06-08 | Eisai Co Ltd | Process for the production of medical preparations having sustained release of therapeutical effect |
| DE3042916A1 (de) * | 1979-06-01 | 1982-07-01 | Joachim 7440 Nürtingen Dudzik | Tablette |
| CA1218604A (en) * | 1981-07-08 | 1987-03-03 | Alec D. Keith | Trinitroglycerol sustained release vehicles and preparations therefrom |
| EP0147780A3 (en) * | 1984-01-03 | 1987-03-11 | Merck & Co. Inc. | Drug delivery device |
| US4927633A (en) * | 1984-03-19 | 1990-05-22 | Alza Corporation | Dispenser for delivering drug to livestock |
| US4685918A (en) * | 1985-02-01 | 1987-08-11 | Merck & Co., Inc. | Lipid osmotic pump |
| ZA889189B (en) * | 1986-06-16 | 1989-08-30 | Merck & Co Inc | Controlled release combination of carbidopa/levodopa |
| US4983400A (en) * | 1986-06-16 | 1991-01-08 | Merck & Co., Inc. | Controlled release combination of carbidopa/levodopa |
| US4940465A (en) * | 1987-05-27 | 1990-07-10 | Felix Theeuwes | Dispenser comprising displaceable matrix with solid state properties |
| US4892778A (en) * | 1987-05-27 | 1990-01-09 | Alza Corporation | Juxtaposed laminated arrangement |
| US4915949A (en) * | 1987-07-13 | 1990-04-10 | Alza Corporation | Dispenser with movable matrix comprising a plurality of tiny pills |
| US4946686A (en) * | 1987-09-24 | 1990-08-07 | Merck & Co., Inc. | Solubility modulated drug delivery system |
-
1991
- 1991-01-23 DE DE4101873A patent/DE4101873C2/de not_active Expired - Lifetime
-
1992
- 1992-01-23 SK SK3692-92A patent/SK278736B6/sk unknown
- 1992-01-23 EP EP92903405A patent/EP0568577B1/de not_active Expired - Lifetime
- 1992-01-23 CZ CS923692A patent/CZ280847B6/cs unknown
- 1992-01-23 CA CA002101164A patent/CA2101164C/fr not_active Expired - Fee Related
- 1992-01-23 JP JP50323992A patent/JP3382940B2/ja not_active Expired - Lifetime
- 1992-01-23 RU RU93051537/14A patent/RU2114619C1/ru not_active IP Right Cessation
- 1992-01-23 RO RO93-01024A patent/RO114737B1/ro unknown
- 1992-01-23 UA UA94051480A patent/UA27848C2/uk unknown
- 1992-01-23 WO PCT/DE1992/000043 patent/WO1992012710A1/de not_active Ceased
- 1992-01-23 DE DE59207852T patent/DE59207852D1/de not_active Expired - Lifetime
- 1992-01-23 AT AT92903405T patent/ATE147264T1/de not_active IP Right Cessation
- 1992-01-23 ES ES92903405T patent/ES2098496T3/es not_active Expired - Lifetime
- 1992-01-23 AU AU11868/92A patent/AU658171B2/en not_active Ceased
- 1992-01-23 DK DK92903405.6T patent/DK0568577T3/da active
- 1992-01-23 US US08/090,163 patent/US5532274A/en not_active Expired - Lifetime
-
1993
- 1993-05-14 LT LTIP555A patent/LT3659B/lt not_active IP Right Cessation
- 1993-06-14 LV LVP-93-567A patent/LV11103B/lv unknown
- 1993-06-22 BG BG97894A patent/BG61677B1/bg unknown
- 1993-07-09 NO NO932159A patent/NO304638B1/no not_active IP Right Cessation
- 1993-07-22 FI FI933304A patent/FI101040B/fi active
-
1994
- 1994-06-29 EE EE9400066A patent/EE03016B1/xx not_active IP Right Cessation
-
1997
- 1997-04-01 GR GR970400667T patent/GR3022993T3/el unknown
Patent Citations (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1243474A (en) | 1968-10-01 | 1971-08-18 | Merck & Co Inc | Compositions comprising l-dopa |
| US3769424A (en) | 1970-10-01 | 1973-10-30 | Merck & Co Inc | Composition and method of treating dopamine deficiency in brain tissue |
| DE3012602A1 (de) | 1979-04-26 | 1980-11-06 | Merrell Toraude & Co | 1-fluor-3-phenyl-2-propanon-derivate und verfahren zu ihrer herstellung |
| BE894376A (fr) | 1981-09-14 | 1983-03-14 | Hoffmann La Roche | Preparation pharmaceutique |
| US4424235A (en) | 1981-09-14 | 1984-01-03 | Hoffmann-La Roche Inc. | Hydrodynamically balanced controlled release compositions containing L-dopa and a decarboxylase inhibitor |
| DE3235093A1 (de) | 1981-09-22 | 1983-04-07 | Akira Suita Osaka Hayashi | Antiparkinsonmittel |
| EP0253490A1 (en) | 1986-06-16 | 1988-01-20 | Merck & Co. Inc. | Controlled release combination of carbidopa/levodopa |
| EP0260236A1 (en) | 1986-08-26 | 1988-03-16 | ASTA Pharma Aktiengesellschaft | Composition comprising L-dopa |
| EP0302693A2 (en) | 1987-08-03 | 1989-02-08 | Merck & Co. Inc. | Device for the controlled release of drugs with donnanlike modulation by charged insoluble resins |
| EP0314206A1 (en) | 1987-09-24 | 1989-05-03 | Merck & Co. Inc. | Solubility modulated drug delivery device |
| EP0320051A1 (en) | 1987-12-11 | 1989-06-14 | Merck & Co. Inc. | Controlled release combination of carbidopa/levodopa |
| DE3841955A1 (de) | 1987-12-31 | 1989-07-13 | Asta Pharma Ag | Synergistische kombination von decarboxylasehemmern und l-dopa-pellets |
| EP0324947A1 (de) | 1987-12-31 | 1989-07-26 | ASTA Medica Aktiengesellschaft | Synergistische Kombination von Decarboxylasehemmern und L-Dopa-Pellets |
Non-Patent Citations (1)
| Title |
|---|
| W. BIRKMAYER ET AL.: "Der L-Dioxyphenylalanin (L-DOPA) Effekt bei der Parkinson-Akinesie", WIEN. KLIN. WOCHENSCHRIFT., 1961, pages 787 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LT3659B (en) | Orally adminsterable drugs for the treatmentof central dopamine deficiency conditions | |
| KR100891887B1 (ko) | 5-메틸-1-페닐-2-(1ｈ)-피리돈을 활성 성분으로서 함유하는의약 제제 | |
| JP4219988B2 (ja) | 高いバイオアベイラビリティーを有するフェノフィブレート医薬組成物及びそれを調製するための方法 | |
| AU676315B2 (en) | Stabilized solid pharmaceutical preparation and method of producing the same | |
| JPH10194969A (ja) | 錠剤組成物 | |
| US5624960A (en) | Orally administrable drugs for the treatment of central dopamine deficiency conditions | |
| CN102413814A (zh) | 用于神经保护和治疗神经变性病症的克拉维酸类物质制剂 | |
| WO2007086891A1 (en) | Levetiracetam formulations and methods for their manufacture | |
| WO2020209350A1 (ja) | 糖尿病治療用口腔内速崩壊錠 | |
| JP2019530727A (ja) | ラモトリギンを含む経口懸濁液用の粉末 | |
| CN1449745A (zh) | 包衣的固体催眠制剂 | |
| US7666860B2 (en) | Melt-formulated, multi-particulate oral dosage form | |
| EP3880171B1 (en) | Ibuprofen-containing oral pharmaceutical formulation | |
| JPH06239756A (ja) | 制酸剤組成物 | |
| HU215191B (hu) | Eljárás Levodopa és Carbidopa hatóanyag-kombinációt tartalmazó, szabályozott hatóanyag-leadású, központi dopaminhiányos állapotok kezeléséhez alkalmas orális gyógyszerkészítmény előállítására | |
| JP2003300874A (ja) | 塩酸プソイドエフェドリン含有固形製剤 | |
| HK40064142B (en) | Ibuprofen-containing oral pharmaceutical formulation | |
| WO2019030773A1 (en) | DICLOFENAC COMPOSITIONS WITH LOW DOSE | |
| DD301037A5 (de) | Peroral applizierbare Arzneiform zur Behandlung zentraler Dopaminmangelzustände | |
| JP2004091373A (ja) | 分解に対する安定性及び含量均一性に優れたメシル酸ペルゴリド含有製剤 | |
| HK1056512B (en) | Coated solid preparation having hypnotic action | |
| HK1106160A (en) | Levetiracetam formulations and methods for their manufacture |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM9A | Lapsed patents |
Effective date: 20040514 |